SPARTA Biodiscovery is a company commercializing the SPARTA® technology, which enables the accurate chemical analysis of nanoparticles in nanoformulations for next-generation therapeutics.

SPARTA Biodiscovery

SPARTA Biodiscovery is a brand-new spin-out company from Imperial College London developing and commercialising the SPARTA® technology. SPARTA® (Single Particle Automated Raman Trapping Analysis) is a breakthrough analytical technology for automated, label-free comprehensive characterisation of nanoformulations. SPARTA® is available through our service offering and in the near future as a benchtop instrument.

We welcome two great new team members this month! Ashkan Roozbeh has joined us as Senior Optical Engineer and Callum Macdonald as Software Engineer! #team!

What a start to the new year! Our co-founder Molly Stevens has been awarded a Damehood in the New Year Honours! https://lnkd.in/eVcPQqAg 
Congratulations Professor Dame Molly Stevens!

How can we use #nanotechnology to tackle antibiotic resistance? One approach is to use nanoparticles as reaction chambers, or #nanoreactors, to convert products released by bacteria into bactericidal agents to locally kill bacteria cells.
Michael Potter, PhD, Molly Stevens and team carefully designed semi-permeable nanoreactors loaded with antimicrobial enzymes to convert glucose into hypochlorite, a potent antimicrobial.
#SPARTA was used to demonstrate the semi-permeability of their nanoreactors on the single particle scale, as well as for detailed characterisation of the carrier chemistry.
Read more here! https://lnkd.in/etF2t7B8

Loading your small molecule API into a lipid delivery system is a challenge.  How does your molecule’s chemistry affect how it loads into #nanoparticles?
#SPARTA looks at the chemical profile of individual nanoparticles, in a rapid, automated, label-free manner, to tell you precisely how heterogeneously your cargoes are loading.
Check out how this has been shown in liposomes and polymer vesicles, including for the commercial #nanoformulation Doxil. #analytics

https://lnkd.in/gjRhJN_8

You spent years finding the right target. Do you have the optimal vector? 

LNP's as a vector have emerged as a leading platform. But, what gives you confidence your proprietary lipid composition or targeting ligand density is well known or characterized? 

#SPARTA can provide unparalleled insight into your formulation's composition in a rapid and automated format down to the single particle level. #nanoformulations #analytics 
https://lnkd.in/epgdJtzG

Join our CEO Jelle Penders speaking today at the 20th Anniversary #bioProcessUK conference of the BioIndustry Association (BIA) at the Next Generation Analytics session to learn how #SPARTA is Enabling #Nanoformulations for Next-Generation Therapeutics!

How well do you know your #nanomedicine? SPARTA looks the individual particle level in an automated and label-free way with minimal sample prep. Learn more today about how #SPARTA can bring you valuable insights!
https://lnkd.in/eVV2VS_n #nanoformulations #analytics

Our co-founder Molly Stevens was recently interviewed by Drug Discovery World! Read the article to find out more about her career highlights and how SPARTA fulfills an unmet need in drug delivery platform development. #nanoformulations #analytics

COM:SPARTABIODISCOVERY

SPARTA Biodiscovery

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

stage

raised capital

Description

peer of

invested in

competitor of

Metrics